Quince Therapeutics Doses First Patient in Phase 3 Trial of EryDex to Treat Ataxia-Telangiectasia

MT Newswires Live06-25

Quince Therapeutics (QNCX) said Tuesday it has dosed the first patient in its phase 3 trial to evaluate the neurological effects of EryDex in patients with Ataxia-Telangiectasia.

The study plans to enroll about 86 patients aged six to nine and about 20 aged 10 or older, the company said, adding that it expects to announce topline results in the second half of 2025 with a potential new drug application submission in 2026.

With the achievement of the first patient enrolled in the study, Quince said it will make a $5 million cash milestone payment to former EryDel shareholders. Quince acquired EryDel in October 2023.

Ataxia Telangiectasia is a rare, inherited genetic disorder that affects the nervous system and immune system.

Price: 0.69, Change: -0.01, Percent Change: -1.56

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2446268825?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-06-25 23:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2446268825","market":"fut","top_or_hot":-1,"title":"Quince Therapeutics Doses First Patient in Phase 3 Trial of EryDex to Treat Ataxia-Telangiectasia","media":"MT Newswires Live","content":"<html><body><p> Quince <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (QNCX) said Tuesday it has dosed the first patient in its phase 3 trial to evaluate the neurological effects of EryDex in patients with Ataxia-Telangiectasia.</p><p>The study plans to enroll about 86 patients aged six to nine and about 20 aged 10 or older, the company said, adding that it expects to announce topline results in the second half of 2025 with a potential new drug application submission in 2026.</p><p>With the achievement of the first patient enrolled in the study, Quince said it will make a $5 million cash milestone payment to former EryDel shareholders. Quince acquired EryDel in October 2023.</p><p>Ataxia Telangiectasia is a rare, inherited genetic disorder that affects the nervous system and immune system.</p><p>Price: 0.69, Change: -0.01, Percent Change: -1.56</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Quince Therapeutics Doses First Patient in Phase 3 Trial of EryDex to Treat Ataxia-Telangiectasia</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQuince Therapeutics Doses First Patient in Phase 3 Trial of EryDex to Treat Ataxia-Telangiectasia\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-25 23:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Quince Therapeutics (QNCX) said Tuesday it has dosed the first patient in its phase 3 trial to evaluate the neurological effects of EryDex in patients with Ataxia-Telangiectasia.The study plans to ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2446268825","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2446268825","pubTimestamp":1719331039,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Quince Therapeutics  said Tuesday it has dosed the first patient in its phase 3 trial to evaluate the neurological effects of EryDex in patients with Ataxia-Telangiectasia.The study plans to enroll about 86 patients aged six to nine and about 20 aged 10 or older, the company said, adding that it expects to announce topline results in the second half of 2025 with a potential new drug application submission in 2026.With the achievement of the first patient enrolled in the study, Quince said it will make a $5 million cash milestone payment to former EryDel shareholders. Quince acquired EryDel in October 2023.Ataxia Telangiectasia is a rare, inherited genetic disorder that affects the nervous system and immune system.Price: 0.69, Change: -0.01, Percent Change: -1.56","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","QNCX":"Quince Therapeutics, Inc.","LENZ":"Therapeutics"},"translate_title":"Quince Therapeutics在EryDex治疗共济失调-毛细血管扩张症的3期试验中为首例患者用药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"QNCX":0.9},"content_text":"Quince Therapeutics (QNCX) said Tuesday it has dosed the first patient in its phase 3 trial to evaluate the neurological effects of EryDex in patients with Ataxia-Telangiectasia.The study plans to enroll about 86 patients aged six to nine and about 20 aged 10 or older, the company said, adding that it expects to announce topline results in the second half of 2025 with a potential new drug application submission in 2026.With the achievement of the first patient enrolled in the study, Quince said it will make a $5 million cash milestone payment to former EryDel shareholders. Quince acquired EryDel in October 2023.Ataxia Telangiectasia is a rare, inherited genetic disorder that affects the nervous system and immune system.Price: 0.69, Change: -0.01, Percent Change: -1.56","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2446268825"}